BioTuesdays

Category - Markets

Profound Medical Logo
Markets

Echelon names Profound Medical as Top Pick

Echelon Wealth Partners has named Profound Medical (TSX:PRN; OTCQX:PRFMF) as a Top Pick with a “buy” rating and $3 price target. The stock closed at 60 cents on Oct. 10. Commenting on Profound’s share price softness in...

October 12, 2018
Immune Design
Markets

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

October 12, 2018
AcelRx Pharma Logo
Markets

Ladenburg ups AcelRx Pharma PT to $10 from $7

Ladenburg Thalmann raised its price target for AcelRx Pharmaceuticals (NASDAQ:ACRX) to $10 from $7 after the FDA released briefing documents ahead of Friday’s meeting to discuss the company’s drug candidate, Dsuvia. The...

October 11, 2018
Quanterix
Markets

Canaccord starts Quanterix at buy; PT $27

Canaccord Genuity initiated coverage of Quanterix (NASDAQ:QTRX) with a “buy” rating and $27 price target. The stock closed at $18.37 on Oct. 9. “We view Quanterix as a precision medicine pure-play well positioned to...

October 10, 2018
LeMaitre Vascular
Markets

Roth ups LeMaitre Vascular to buy; PT cut to $34

Roth Capital Partners upgraded LeMaitre Vascular (NASDAQ:LMAT) to “buy” from “neutral” but reduced its price target to $34 from $39 after the company reported in-line EPS for the third quarter of 2018, despite a $1.8...

October 8, 2018
Evotec
Markets

Ladenburg starts Evotec at buy; PT €22.50

Ladenburg Thalmann initiated coverage of German-based Evotec (FSE:EVT) with a “buy” rating and price target of €22.50. The stock closed at €18.53 on Oct. 3. Evotec is a global drug discovery and services company that...

October 4, 2018
STRATA Skin Sciences
Markets

HCW ups STRATA Skin Sciences PT to $5 from $3

H.C. Wainwright raised its price target for STRATA Skin Sciences (NASDAQ:SSKN) to $5 from $3 after the company announced new clinical data that is expected to drive patient growth and retention. The stock closed at $3...

October 2, 2018
Inovio Pharmaceuticals
Markets

Stifel resumes coverage of Inovio Pharma at buy; PT $8

Stifel resumed coverage of Inovio Pharmaceuticals (NASDAQ:INO) with a “buy” rating and $8 price target, saying the implied risk/reward appears palatable. The stock closed at $5.35 on Oct. 1. Analyst Steven Willey writes...

October 2, 2018
Oncolytics Biotech
Markets

Ladenburg starts Oncolytics Biotech at buy; PT $22

Ladenburg Thalmann launched coverage of Oncolytics Biotech (NASDAQ:ONCY) with a “buy” rating and $22 price target. The stock closed at $3.86 on Sept. 28. Oncolytics is developing oncolytic virus (OV) therapy for cancer...

October 1, 2018